Ad
Wednesday, 21 August 2019
AstraZeneca Imfinzi combination fails advanced lung cancer study
A combination of AstraZeneca's lung cancer drug Imfinzi and an experimental treatment failed to extend the lives of patients with advanced non-small cell lung cancer (NSCLC) and high levels of gene mutations, the drugmaker said on Wednesday.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment